Date: 2016-06-17
Type of information: Construction of new premises
Compound:
Company: Valeant Pharmaceuticals (Canada)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On June 17, 2016, Valeant Pharmaceuticals announced that its wholly-owned subsidiary Valeant Canada is expanding its Canadian manufacturing and export capacity with investments totaling $27.5 million in its Steinbach, Manitoba and Laval, Quebec manufacturing facilities. Valeant will invest $15 million in its Steinbach, Manitoba facility by the end of 2016, including $7 million in upgrades to product manufacturing technology and $8 million for the transfer of North American production of Xifaxan® (rifaximin), a drug prescribed to relieve symptoms of hepatic encephalopathy and irritable bowel syndrome and Apriso® (mesalamine), a drug used to treat ulcerative colitis. These investments will support the facility's growth and expand its role as a key exporter of leading healthcare products while ensuring robust security for products traveling through international distribution channels. Since 2012, Valeant has transferred 27 technologies to Steinbach for manufacturing. Valeant also announced $12.5 million of investments in its Laval, Quebec facility, which includes $10 million to upgrade product manufacturing technology, as well as $2.5 million associated with the transfer of production of Arestin® (minocycline hydrochloride) to Laval. The transfer of Arestin®, an antibiotic treatment for periodontal disease, will create 15 new engineering and production jobs and builds upon the transfer of Jublia® production to Quebec earlier this year. Since 2012, Valeant has transferred numerous technologies to Laval, resulting in the production of 67 new products.
Financial terms:
Latest news:
